ClinicalTrials.gg
CompletedNCT04274049Updated Sep 20, 2024

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)

A Phase 3 interventional study of NL003 and Normal Saline in Arterial Occlusive Disease, Ischemia and Ulcers, sponsored by Beijing Northland Biotech. Co., Ltd.. Completed at 21 sites in China. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-20.

Primary conditionChronic Limb-Threatening IschemiaRegistry: Arterial Occlusive DiseasesReclassifiedWhy we changed it
Registry
Arterial Occlusive Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Limb-Threatening Ischemia
Why
  1. The study's title name Chronic Limb-Threatening Ischemia, a narrower term within Arterial Occlusive Diseases.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Beijing Northland Biotech. Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Aug 2019, registered Jan 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Chronic Limb-Threatening Ischemia with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · China.

Enrollment
2nd of 15
242 · median 120
Started
2019
with 2 others
Phase 3
2 of 23
none open now
Registered
8th of 23
by date
Lead sponsor
4 of 23
Beijing Northland Biotech. Co., Ltd.

Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in China, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 3, and was the 8th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

7 of the 23 studies in Chronic Limb-Threatening Ischemia with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Chronic Limb-Threatening Ischemia with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether intramuscular injections of NL003 into the calf is safe and effective in the treatment of critical limb ischemia

Read the detailed description

Management of CLI process consumes a significant amount of healthcare resources,and the new therapeutic approaches are required.

Hepatocyte growth factor (HGF) has been shown to be a potent angiogenic growth factor stimulating the growth of endothelial cells and migration of vascular smooth muscle cells. Because of its pluripotent capabilities, increasing the availability of HGF in ischemic tissues to achieve therapeutic angiogenesis has been a growing area of research.

This study will use NL003, which is a DNA plasmid that contains novel genomic cDNA hybrid human HGF coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723. As there are currently no approved drugs that can reverse CLI and as most patients have exhausted surgical and endovascular intervention options, inducing angiogenesis in the affected limb with NL003 may result in an increase in tissue perfusion, which, in turn improve wound healing, reduce pain and improve limb salvage rates.

03

Conditions studied

  • Arterial Occlusive Disease
  • Ischemia
  • Ulcers
  • Peripheral Vascular Disease

Keywords

  • HGF
  • Gene
  • Critical Limb Ischemia
04

In context

Chronic Limb-Threatening Ischemia Reclassified

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

This study's enrollment of 242 is above the median of 41 across 240 interventional studies indexed under Chronic Limb-Threatening Ischemia.

Browse Chronic Limb-Threatening Ischemia studies →

Lead sponsor

Beijing Northland Biotech. Co., Ltd. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arterial Occlusive Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. At the age of 20 and 80 (at the time of signing the ), both male and female.

      1. According to DSA or CTA, patients diagnosed with lower limb arterial ischemic disease based on the medical history and clinical manifestations and with Rutherford grade 5 (with ulcer) must meet the substandardProspective.(if both limbs of the subject suffer from lower limb arterial ischemic disease, it is up to the investigator to select one limb for the study.)Resting ankle systolic pressure (dorsal foot artery or posterior tibial artery) ≤70mmHg or ABI≤0.5 or TcPO2 \< 30mmHg;In the first 3 months after randomized inclusion, DSA or CTA confirmed severe stenosis (≥70%) or occlusion of superficial femoral artery or popliteal artery or inferior knee artery.
      1. Patients with chronic lower limb arterial ischemia complicated with ulceration also met the following requirements: when signing the informed consent, the ischemic ulcer of the artery lasted at least 2 weeks;When signing the informed consent, the area of a single ulcer is no more than 10cm2;If there are multiple ulcers in the affected limb selected at the time of signing the informed consent, the total number of ulcers shall not exceed 3.Basic ulcer care (according to standard ulcer care procedure) should be maintained during the test to avoid aggravation of infection.The ulcer did not expose bone or joint capsule.If there is gangrene, only partial toe gangrene.
      1. Agreed to use the basic treatment drugs as required during the test, and kept a complete record of the subjects' diaries on time. The compliance of the basic treatment drugs and the subjects' diaries during the screening period was ≥70%.
      1. Agree to use appropriate measures during the experiment;Female subjects of reproductive age, blood pregnancy test negative.
      1. Signed informed consent.

Exclusion criteria

Exclusion Criteria:

    1. Patients with acute lower limb ischemia or acute exacerbation of chronic lower limb ischemia.

      1. Vascular reconstruction (bypass or intravascular therapy) or sympathetic resection or amputation was performed within 4 weeks prior to the signing of the .
      1. Due to the surgical operation, the patient was still in the postoperative risk period, and the researcher judged that it was not suitable for the participant.
      1. Main-iliac artery stenosis ≥70%.
      1. Severe limb infection (cellulitis, osteomyelitis, etc.), distal fascia or bone exposure were observed.
      1. Cardiac function class belongs to Ⅳ grading standards (see appendix 1).
      1. Cerebral infarction, cerebral hemorrhage, myocardial infarction or unstable angina pectoris occurred within 3 months before signing the informed consent.
      1. hypertension (systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg when taking three or more antihypertensive drugs).
      1. Proliferative retinopathy and retinopathy examination is not available.
      1. Inability to accurately describe symptoms and emotions.
      1. Severe liver disease with uncompensated cirrhosis, jaundice, ascites or hemorrhagic varices.
      1. Current recipients of or chemoradiotherapy.
      1. Anti-hiv antibody positive, anti- antibody positive and surface antigen positive (if the subject is HBsAg positive and HBV DNA in peripheral blood is combined, the researcher believes that the subject's chronic hepatitis b is stable and will not increase the risk of the subject, the subject can be selected).
      1. Results of laboratory examination during screening period: \< 80g/L, white blood cell count \< 3.0×109/L, \< 75×109/L, or ALT >, upper limit of normal serum creatinine > was 3 times, or other laboratory examination indicators showed abnormalities that researchers thought might affect the evaluation of test results.
      1. Poor blood glucose control after treatment (glycosylated hemoglobin > 10%).
      1. Previously diagnosed with malignant tumor, or any of the following test results determined by the investigator to be at risk of tumor: fecal occult blood test;Chest X-ray examination or chest CT examination;Alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA) and ca19-9;Male subjects, prostate specific antigen test (PSA, free PSA);Female subjects: cervical smear (Pap), mammography/b-ultrasound, ca-125;The investigators determined that additional tests were necessary to eliminate the tumor risk.
      1. In the opinion of the investigators, patients with comorbidities that affect safety and efficacy evaluation, or those with a predicted survival of less than 12 months.
      1. Frequent drinkers within the 12 months prior to the signing of the informed consent, i.e., those who drank more than 14 units of alcohol per week (1 unit =360 mL beer or 45 mL alcohol of 40% spirits or 150 mL wine) or substance abusers.
      1. Participate in other clinical trials within 3 months before signing the informed consent.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    investigational produc

    Patients in this treatment group will receive 8mg NL003 respective in D0、14、28

    Genetic: NL003

  • Placebo comparator
    Placebo

    Patients in this group will receive normal saline respective in D0、14、18

    Other: Normal Saline

Interventions

  • GeneticNL003

    Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)

    Also known as: HGF plasmid, pCK-HGF-X7

  • OtherNormal Saline

    Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )

    Also known as: Placebo

07

What researchers measure

Primary outcomes

  1. Percentage of ulcer complete healing

    1.At D180 visit, subjects intended to observe the healing of all arterial ischemic ulcers in the limb;2.Ulcer healing criteria: skin epidermal cell regeneration without secretion.

    Time frame: Day180

Secondary outcomes

  1. The time when the ulcer finally heals completely

    The time between the first use of the study drug and the final full healing of the ulcer.

    Time frame: Day14,Day28,Day60,Day90,Day120,Day180

  2. Percentage of cases with ulcer area reduced by ≥50% from baseline

    The ulcer area at the last visit was 50% less than the baseline case percentage.

    Time frame: Day180

  3. Percentage of new ulcer or gangrene cases

    The percentage of new ulcer or gangrene cases after use of the study drug.

    Time frame: Day14,Day28,Day60,Day90,Day120,Day180

  4. Rate of complete disappearance of pain

    Rate of complete disappearance of pain.

    Time frame: Day180

  5. Percentage of cases with a 50% reduction in pain score from baseline

    A 50% reduction in pain score from baseline at the last visit.

    Time frame: Day180

  6. Changes in pain score from baseline

    The severity of critical Limb ischemia was assessed by Rutherford grading at screening, D14, D28, D60, D90, and D180, respectively.

    Time frame: Day14,Day28,Day60,Day90,Day120,Day180

  7. Changes in quality of life scores from baseline

    The quality of life score questionnaire was conducted to evaluate the subjective perception of Critical Limb Ischemia, including the subjects' perception of quality of life, health, or other aspects of life.

    Time frame: Day14,Day28,Day60,Day90,Day120,Day180

  8. Changes in Rutherford grading from baseline

    The severity of critical Limb ischemia was assessed by Rutherford grading at screening, D14, D28, D60, D90, and D180, respectively.

    Time frame: Day14,Day28,Day60,Day90,Day120,Day180

  9. Changes to the ABI from the baseline

    Ankle-brachial index (ABI) refers to the ratio of systolic blood pressure of the anterior tibial artery (dorsal foot artery) or posterior tibial artery to the systolic blood pressure of the brachial artery.Participants were tested for ankle-brachial index (ABI).

    Time frame: Day60,Day90,Day120,Day180

  10. The percentage of patients who undergo revascularization (open surgery or interventional therapy) has a high amputation rate of mortality

    The percentage of patients who undergo revascularization (open surgery or interventional therapy) has a high amputation rate of mortality.

    Time frame: Day180

08

Study locations

21 sites
  • Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
  • Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • Zhongshan Hospital Xiamen University
    Xiamen, Fujian, China
  • Zhangzhou Municipal Hospital of Fujian Province
    Zhangzhou, Fujian 363000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410000, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410000, China
  • Xuzhou Mining Group General Hospital
    Xuzhou, Jiangsu 221006, China
  • The First Affiliated Hospital of Zhengzhou University
    Chang chun, Jilin, China
  • Affiliated Hospital of Inner Mongolia Medical University
    Baotou, Neimenggu, China
  • Chifeng Municipal Hospital
    Chifeng, Neimenggu 024000, China
  • Affiliated Hospital of Shandong University of Traditional Chinese Medicine
    Jinan, Shandong, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266003, China
  • Qingdao Hiser Hospital Affiliated of Qingdao University(Qingdao Traditional Chinese Medicine Hospital)
    Qingdao, Shandong, China
  • Fudan University Affiliated Pudong Medical Center
    Shanghai, Shanghai, China
  • Shanghai 9th People's Hospital Affiliated to Shanghai JiaoTong University, School of Medicine;
    Shanghai, Shanghai, China
  • Shanxi Provincial People's Hospital
    Taiyuan, Shanxi 030012, China
  • First Affiliated Hospital of Xi 'an Jiaotong University
    XiAn, Shanxi 710061, China
  • The First Affiliated Hospital,Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
  • zhongshan Hospital Affiliated of Dalian University
    Dalian, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Dec 2023, 51 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2020
First posted
Feb 18, 2020
StartActual
Aug 28, 2019
Primary completionActual
Dec 23, 2023
CompletionActual
Dec 23, 2023
Last update
Sep 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04274049
Lead sponsor
Beijing Northland Biotech. Co., Ltd.
Responsible party
Sponsor
First posted
Feb 18, 2020
Start date
Aug 28, 2019
Primary completion
Dec 23, 2023
Completion
Dec 23, 2023
Last update
Sep 20, 2024

Study contacts

Changwei Liu, MD
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion